Modulation of α-synuclein fibrillization by ring-fused 2-pyridones: templation and inhibition involve oligomers with different structure
- PMID: 23399432
- DOI: 10.1016/j.abb.2013.01.012
Modulation of α-synuclein fibrillization by ring-fused 2-pyridones: templation and inhibition involve oligomers with different structure
Abstract
In a recent study we discovered that a ring-fused 2-pyridone compound triggered fibrillization of a key protein in Parkinson's disease, α-synuclein. To reveal how variations in compound structure affect protein aggregation, we now prepared a number of strategic analogs and tested their effects on α-synuclein amyloid fiber formation in vitro. We find that, in contrast to the earlier templating effect, some analogs inhibit α-synuclein fibrillization. For both templating and inhibiting compounds, the key species formed in the reactions are α-synuclein oligomers that contain compound. Despite similar macroscopic appearance, the templating and inhibiting oligomers are distinctly different in secondary structure content. When the inhibitory oligomers are added in seed amounts, they inhibit fresh α-synuclein aggregation reactions. Our study demonstrates that small chemical changes to the same central fragment can result in opposite effects on protein aggregation.
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
-
Mechanisms of protein oligomerization: inhibitor of functional amyloids templates α-synuclein fibrillation.J Am Chem Soc. 2012 Feb 22;134(7):3439-44. doi: 10.1021/ja209829m. Epub 2012 Feb 9. J Am Chem Soc. 2012. PMID: 22260746 Free PMC article.
-
A blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD).J Biol Chem. 2013 Jun 14;288(24):17579-88. doi: 10.1074/jbc.M112.434787. Epub 2013 May 1. J Biol Chem. 2013. PMID: 23637226 Free PMC article.
-
beta-Sheet-breaking peptides inhibit the fibrillation of human alpha-synuclein.Biochem Biophys Res Commun. 2009 Oct 2;387(4):682-7. doi: 10.1016/j.bbrc.2009.07.083. Epub 2009 Jul 19. Biochem Biophys Res Commun. 2009. PMID: 19622344
-
Assays for α-synuclein aggregation.Methods. 2011 Mar;53(3):295-305. doi: 10.1016/j.ymeth.2010.12.008. Epub 2010 Dec 14. Methods. 2011. PMID: 21163351 Review.
-
Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.Biochemistry. 2003 Jul 8;42(26):7871-8. doi: 10.1021/bi030086j. Biochemistry. 2003. PMID: 12834338 Review.
Cited by
-
Pathogenesis of Parkinson disease--the gut-brain axis and environmental factors.Nat Rev Neurol. 2015 Nov;11(11):625-36. doi: 10.1038/nrneurol.2015.197. Epub 2015 Oct 27. Nat Rev Neurol. 2015. PMID: 26503923 Review.
-
Different Structural Conformers of Monomeric α-Synuclein Identified after Lyophilizing and Freezing.Anal Chem. 2018 Jun 5;90(11):6975-6983. doi: 10.1021/acs.analchem.8b01264. Epub 2018 May 22. Anal Chem. 2018. PMID: 29750859 Free PMC article.
-
Direct Correlation Between Ligand-Induced α-Synuclein Oligomers and Amyloid-like Fibril Growth.Sci Rep. 2015 May 28;5:10422. doi: 10.1038/srep10422. Sci Rep. 2015. PMID: 26020724 Free PMC article.
-
α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.Future Med Chem. 2017 Jun;9(10):1039-1053. doi: 10.4155/fmc-2017-0016. Epub 2017 Jun 20. Future Med Chem. 2017. PMID: 28632413 Free PMC article. Review.
-
Bacterial Chaperones CsgE and CsgC Differentially Modulate Human α-Synuclein Amyloid Formation via Transient Contacts.PLoS One. 2015 Oct 14;10(10):e0140194. doi: 10.1371/journal.pone.0140194. eCollection 2015. PLoS One. 2015. PMID: 26465894 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources